Abstract
Background: Inhibition of fibroblast (FB) proliferation and hyaluronic acid (HA) production may be a therapeutic approach to Graves’ ophthalmopathy (GO). The flavonoid quercetin has a wide range of activities, including reduction of FB growth. Aim: To investigate the effects of quercetin in orbital FB from GO patients and control subjects. Methods: Primary cultures of orbital FB were treated with quercetin or with its glycosides rutin and quercitrin. Cell proliferation, necrosis, apoptosis, HA production, and cell cycle were measured. Results: Beginning at a 30 µM concentration, quercetin, but not rutin and quercitrin, reduced cell proliferation, with no difference between GO and control FB. The effect of quercetin on proliferation was due to necrosis and cell cycle blockade, whereas apoptosis was unaffected. Quercetin reduced HA in the cell media, with no difference between GO and control FB. Conclusions: Quercetin reduces cell proliferation and HA release in orbital FB. Whether these initial findings have any potential for the use of quercetin in the clinical practice remains to be established.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev 2000, 21: 168–99.
Bartalena L, Wiersinga WM, Pinchera A. Graves’ ophthalmopathy: state of the art and perspectives. J Endocrinol Invest 2004, 27: 295–301.
Marcocci C, Pinchera A, Marinò M. A treatment strategy for Graves’ orbitopathy. Nat Clin Pract Endocrinol Metab 2007, 3: 430–6.
Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr Rev 2003, 24: 802–35.
Burch HB, Wartofsky L. Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993, 14: 747–93.
Garrity JA, Bahn RS. Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol 2006, 142: 147–53.
Marinò M, Morabito E, Altea MA, et al. Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves’ ophthalmopathy treated successfully with glucocorticoids themselves. J Endocrinol Invest 2005, 28: 280–4.
Marinò M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, Marocci C. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves’ ophthalmopathy. Thyroid 2004, 14: 403–6.
Terwee CB, Wiersinga WM. Graves’ quality of life. Ophthalmology 2007, 114: 1416–7; author reply 7–8.
Williamson G, Manach C. Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am J Clin Nutr 2005, 81 (Suppl): 243S–55S.
Mennen LI, Walker R, Bennetau-Pelissero C, Scalbert A. Risks and safety of polyphenol consumption. Am J Clin Nutr 2005, 81 (Suppl): 326S–9S.
Cushnie TP, Lamb AJ. Antimicrobial activity of flavonoids. Int J Antimicrob Agents 2005, 26: 343–56.
Woodman OL, Chan E. Vascular and anti-oxidant actions of flavonols and flavones. Clin Exp Pharmacol Physiol 2004, 31: 786–90.
Ramos S. Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention. J Nutr Biochem 2007, 18: 427–42.
Phan TT, Sun L, Bay BH, Chan SY, Lee ST. Dietary compounds inhibit proliferation and contraction of keloid and hypertrophic scar-derived fibroblasts in vitro: therapeutic implication for excessive scarring. J Trauma 2003, 54: 1212–24.
Phan TT, See P, Tran E, et al. Suppression of insulin-like growth factor signalling pathway and collagen expression in keloid-derived fibroblasts by quercetin: its therapeutic potential use in the treatment and/or prevention of keloids. Br J Dermatol 2003, 148: 544–52.
Phan TT, Lim IJ, Chan SY, et al. Suppression of transforming growth factor beta/smad signaling in keloid-derived fibroblasts by quercetin: implications for the treatment of excessive scars. J Trauma 2004, 57: 1032–7.
Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 1997, 47: 9–14.
Singer CA, Figueroa-Masot XA, Batchelor RH, Dorsa DM. Themitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J Neurosci 1999, 19: 2455–63.
Chien SY, Wu YC, Chung JG, et al. Quercetin-induced apoptosis acts through mitochondrial- and caspase-3-dependent pathways in human breast cancer MDA-MB-231 cells. Hum Exp Toxicol 2009, 28: 493–503.
Jung JH, Lee JO, Kim JH, et al. Quercetin suppresses HeLa cell viability via AMPK-induced HSP70 and EGFR down-regulation. J Cell Physiol 2010, 223: 408–14.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lisi, S., Botta, R., Lemmi, M. et al. Quercetin decreases proliferation of orbital fibroblasts and their release of hyaluronic acid. J Endocrinol Invest 34, 521–527 (2011). https://doi.org/10.3275/7321
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.3275/7321